Full Text
PMS48 Tocilizumab in Methotrexate-Intolerant or Contraindicated Patients – A Cost-Utility Model for the UK

Abstract

Authors

D. Harland C. Gibbons A. Diamantopoulos H. Pang C. Huertas F. Dejonckheere

Back to Volume 15, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×